Mats Andersson
Mats Andersson, born 1954, is a Swedish financier and asset manager. After previous work at Warburg, Deutsche Bank, and Skandia Liv, he assumed the role as CEO for one of Sweden's major pension funds Fjärde AP-fonden (AP4) where he led the work to redirect investments in the energy sector towards fossil free companies within the government directive Fossilfritt Sverige (Fossil Free Sweden) that engages more than 200 companies, municipalities, counties, regions, and other organizations. He also actively collaborated with the United Nations to raise awareness of the risks climate change brings, from a finance and investment perspective.Andersson was a driving force behind the project Portfolio Decarbonization Coalition (PDC) that was founded and co-financed by AP4 along with United Nations Environment Programme Finance Initiative (UNEP FI), Amundi, and the Carbon Disclosure Project (CDP). The initiative was implemented by Andersson by having AP4 significantly reduce or let go entirely of held shares in American companies with a large carbon footprint, combined with a strategy for investments on emerging markets in companies with a small footprint.
Andersson was awarded the Chief Investment Officer's Lifetime Achievement Award in 2016. In 2015 he was ranked fifth on the Financial News "100 Most Influential List" in the pension fund category, and the same year fourth on the Sovereign Wealth Fund Institutes "Public Investor 100" list.
He left AP4 in March 2016 to, among other things, act as Vice Chairman of the Global Challenges Foundation with special focus on global governance and global catastrophic risks. In December 2016 he was appointed Royal Commissioner by the Swedish government to "map how the market for green bonds can be promoted. Provided by Wikipedia
Showing 1 - 12 results of 12 for search 'Mats Andersson', query time: 0.05s
Refine Results
-
1
Marginal Railway Infrastructure Costs in a Dynamic Context by Mats Andersson
Published 2008-09-01
Article -
2
Global Search Strategies for Solving Multilinear Least-Squares Problems by Mats Andersson, Oleg Burdakov, Hans Knutsson, Spartak Zikrin
Published 2012-04-01
Article -
3
Phase 1 Trial With the Cell-Based Immune Primer Ilixadencel, Alone, and Combined With Sorafenib, in Advanced Hepatocellular Carcinoma by Magnus Rizell, Magnus Rizell, Malin Sternby Eilard, Malin Sternby Eilard, Mats Andersson, Mats Andersson, Bengt Andersson, Alex Karlsson-Parra, Alex Karlsson-Parra, Peter Suenaert
Published 2019-01-01
Article -
4
-
5
-
6
-
7
High-throughput biochemical fingerprinting of Saccharomyces cerevisiae by Fourier transform infrared spectroscopy. by Achim Kohler, Ulrike Böcker, Volha Shapaval, Annabelle Forsmark, Mats Andersson, Jonas Warringer, Harald Martens, Stig W Omholt, Anders Blomberg
Published 2015-01-01
Article -
8
-
9
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3 by Karel Pavelka, Alan Kivitz, Eva Dokoupilova, Ricardo Blanco, Marco Maradiaga, Hasan Tahir, Luminita Pricop, Mats Andersson, Aimee Readie, Brian Porter
Published 2017-12-01
Article -
10
Biomarkers of chronic airflow limitation and COPD identified by mass spectrometry by Magnus Molin, Anne Incamps, Manon Lemasson, Mats Andersson, Eleftheria Pertsinidou, Marieann Högman, Karin Lisspers, Björn Ställberg, Anders Sjölander, Andrei Malinovschi, Christer Janson
Published 2024-02-01
Article -
11
Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3) by Peter Nash, Philip J. Mease, Iain B. McInnes, Proton Rahman, Christopher T. Ritchlin, Ricardo Blanco, Eva Dokoupilova, Mats Andersson, Radhika Kajekar, Shephard Mpofu, Luminita Pricop, on behalf of the FUTURE 3 study group
Published 2018-03-01
Article -
12
The association between specific IgE antibodies to component allergens and allergic symptoms on dog and cat exposure among Korean pet exhibition participants by Sung-Yoon Kang, MD, PhD, Min-Suk Yang, MD, PhD, Magnus P. Borres, MD, PhD, Mats Andersson, MSc, Sang Min Lee, MD, PhD, Sang Pyo Lee, MD, PhD
Published 2022-11-01
Article